Search

Displaying results 3201 - 3210 of 7479 in total
  1. Drug

    KRN-5500

    go.drugbank.com/drugs/DB15215
    Investigational

    KRN-5500 is under investigation in clinical trial NCT00002923 (KRN5500 in Treating Patients With Metastatic Solid Tumors).

  2. Drug

    Propacetamol

    go.drugbank.com/drugs/DB09288
    Investigational

    Propacetamol is a non-opioid analgesic devoid of the major contraindications. It is a derivative of acetaminophen, or paracetamol, with the molecular formula glycine, N, N-diethyl-,4-(acetylamino)phenyl ester. Propacetamol is a parentera...

  3. Drug

    Etanercept

    go.drugbank.com/drugs/DB00005
    ApprovedInvestigational

    Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1. The Fc component of etanercept contains the CH2 ...

  4. Drug

    Eptinezumab

    go.drugbank.com/drugs/DB14040
    ApprovedInvestigational

    Eptinezumab is a fully-humanized IgG1 antibody manufactured using yeast (Pichia pastoris) and developed by Lundbeck Seattle Biopharmaceuticals. Eptinezumab has been specifically designed to bind to both alpha and beta forms of the human ...

  5. Drug

    Ecallantide

    go.drugbank.com/drugs/DB05311
    Approved

    Apart from its FDA and EMA indication, ecallantide has been used off label in the management of nonhistaminergic angioedema, not due to HAE [A32017].

  6. Drug

    Trifarotene

    go.drugbank.com/drugs/DB12808
    ApprovedInvestigational

    [A187081] Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects

  7. Drug

    Flecainide

    go.drugbank.com/drugs/DB01195
    ApprovedInvestigationalWithdrawn

    [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.

  8. Drug

    Acrivastine

    go.drugbank.com/drugs/DB09488
    Approved

    Acrivastine is currently available in combination with pseudoephedrine as the FDA-approved product Semprex-D. … As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension

    Mixtures: Semprex-D, Semprex D
  9. Drug

    EP-1043

    go.drugbank.com/drugs/DB06118
    Experimental

    EP-1043 is an epitope-based recombinant protein vaccine designed to induce HIV-1 specific helper T-lymphocyte (HTL) responses.

  10. Drug

    DR-01

    go.drugbank.com/drugs/DB18258
    Investigational

    DR-01 is a monoclonal antibody directed against human CD94.